Oracle’s rapid OCI cloud and AI growth signal a high-upside phase. Discover projected 27% gains and market drivers.

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...

Global enterprise cloud provider Oracle Corporation is pushing its multicloud and artificial intelligence strategy into a new phase, deploying ultra-high-density GPU clusters, open standards and ...